- Home
- RIGL vs ARDC Comparison
RIGL vs ARDC Comparison
Compare RIGL & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ARDC
- Stock Information
- Founded
- RIGL 1996
- ARDC 2012
- Country
- RIGL United States
- ARDC United States
- Employees
- RIGL N/A
- ARDC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ARDC Investment Managers
- Sector
- RIGL Health Care
- ARDC Finance
- Exchange
- RIGL Nasdaq
- ARDC Nasdaq
- Market Cap
- RIGL 335.5M
- ARDC 344.2M
- IPO Year
- RIGL 2000
- ARDC N/A
- Fundamental
- Price
- RIGL $38.85
- ARDC $14.71
- Analyst Decision
- RIGL Buy
- ARDC
- Analyst Count
- RIGL 5
- ARDC 0
- Target Price
- RIGL $38.20
- ARDC N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- ARDC 115.8K
- Earning Date
- RIGL 08-05-2025
- ARDC 01-01-0001
- Dividend Yield
- RIGL N/A
- ARDC 9.84%
- EPS Growth
- RIGL N/A
- ARDC N/A
- EPS
- RIGL 5.43
- ARDC N/A
- Revenue
- RIGL $267,921,000.00
- ARDC N/A
- Revenue This Year
- RIGL $59.93
- ARDC N/A
- Revenue Next Year
- RIGL N/A
- ARDC N/A
- P/E Ratio
- RIGL $7.14
- ARDC N/A
- Revenue Growth
- RIGL 105.62
- ARDC N/A
- 52 Week Low
- RIGL $12.66
- ARDC $11.56
- 52 Week High
- RIGL $43.72
- ARDC $14.30
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- ARDC 66.23
- Support Level
- RIGL $39.00
- ARDC $14.53
- Resistance Level
- RIGL $42.08
- ARDC $14.64
- Average True Range (ATR)
- RIGL 2.32
- ARDC 0.10
- MACD
- RIGL -0.37
- ARDC 0.00
- Stochastic Oscillator
- RIGL 53.26
- ARDC 100.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).